Pfizer Announces Results From Trial Of AROMASIN In Postmenopausal Women With Hormone Sensitive Early Breast Cancer

News — By on December 15, 2008 at 4:00 am

Pfizer today announced results from a first planned analysis of the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter) trial. TEAM was originally designed in 2001 as a comparison of 5 years of upfront AROMASIN® (exemestane tablets) vs. tamoxifen. In 2004, based on results of Intergroup Exemestane Study (IES) the TEAM trial design was revised; the tamoxifen arm was converted into a tamoxifen/AROMASIN sequencing arm.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback